Screener
BioCryst Pharmaceuticals BCRX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 119,785 | 133,567 | 977,796 | 257,874 |
| Income (loss) from operations | 98,465 | 29,786 | (603,133) | 51,013 |
| Other income (expense): | ||||
| Interest income | 2,434 | 2,516 | 4,690 | 5,540 |
| Interest expense | (21,712) | (21,582) | (41,491) | (45,076) |
| Foreign currency gains (losses), net | 27 | (63) | (198) | (62) |
| Loss on extinguishment of debt | — | (4,171) | — | (4,171) |
| Other income (expense), net | 260 | — | (1,202) | — |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's interest income?
- BioCryst Pharmaceuticals (BCRX) reported interest income of $2.43M in Q2 2026.
- How has BioCryst Pharmaceuticals's interest income changed year-over-year?
- BioCryst Pharmaceuticals's interest income decreased by 3.3% year-over-year, from $2.52M to $2.43M.
- What is the long-term trend for BioCryst Pharmaceuticals's interest income?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's interest income has grown at a 27.7% compound annual growth rate (CAGR), from $5.13M to $10.67M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about BioCryst Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude